Researchers found that there was a significant decrease in food intake, appetite, and carb and sugar cravings at the end of the 8-week period
(n.d.) State of the geriatric workforce
Glucagon-like peptide-1 receptor (GLP-1) agonists, widely used to treat obesity and diabetes, may also improve key outcomes for patients with Crohns disease, according to a large real-world study presented during the 2026 Crohns & Colitis Congress, a partnership of AGA and the Crohn's & Colitis Foundation, taking place in Las Vegas
However, these benefits depend on careful patient selection, informed consent, and ongoing clinical oversight
By controlling these variables, you empower yourself to uncover clear, unambiguous insights from your experiments